High risk of thromboemboli early after bioprosthetic cardiac valve replacement

Heras, Magda; Chesebro, James H.; Fuster, Valentı́n; Penny, W. J.; Grill, Diane E.; Bailey, Kent R.; Danielson, Gordon K.; Orszulak, Thomas A.; Pluth, James R.; Puga, Francisco J.; Schaff, Hartzell V.; Larson-Keller, Jeffrey J.

doi:10.1016/0735-1097(94)00563-6

Cited by 283 publications

(189 citation statements)

References 25 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…11 In our study, most common valve involved with obstruction was mitral 17(73.9%) patients followed by aortic valve 6 (26.1%) patients. In a study by Gupta et al, 87.3% of the PVT episodes occurred in the mitral position.…”

Section: Discussionmentioning

confidence: 45%

Prosthetic valve thrombosis in a tertiary cardiac centre

et al. 2017

View full text Add to dashboard Cite

Background and Aims: Prosthetic valve thrombosis remains a major complication of valve replacement surgeries in Nepal. A number of patients present with thrombotic complications mainly due to poor anticoagulation status with irregular INR checkup at the remote areas of Nepal. Thrombolysis is the preferred method in the management of stuck valve patients due to financial issues . We aimed to retrospectively study the clinical profile and management trends of stuck prosthetic valveMethods: A one year retrospective data of 23 patients (Jan 2015 - Jan 2016) admitted with diagnosis of prosthetic valve thrombosis were studied. The demographic profile, clinical parameters and in hospital outcome were analysed.Results: Out of 23 patients, majority were female (52.2%) with the age group 13-49 years (mean = 35). Sixteen patients (69.6%) presented with INR value < 1.5 at admission. Twenty patients ( 86.9%) were thrombolysed with streptokinase while 3 patients ( 13.1 %) were subjected to treatment with tenecteplase . Valve thrombosis was most common at the mitral position 17 (73.9%) patients. In hospital mortality was seen in 5 ( 21.7%) patients and there were no major bleeding events or new stroke noted.Conclusion: Majority of patients with prosthetic valve thrombosis presented with a subtherapeutic INR value. Thrombolysis can be a useful option in the management of prosthetic valve thrombosis patients in a less resourceful country.Nepalese Heart Journal 2017; 14(1): 9-11

show abstract

Section: Discussionmentioning

confidence: 45%

Prosthetic valve thrombosis in a tertiary cardiac centre

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Nevertheless, structural valve deterioration is well known with surgical bioprostheses, and definitive assessments of valve durability will require much longer follow-up. [24][25][26] A design limitation of transcatheter aortic valves has been paravalvular regurgitation, which results from incomplete circumferential apposition of the prosthesis with the annulus. Several reports have indicated a relation between paravalvular regurgitation and mortality, but the certainty of these findings has been limited by the lack of standardization of methods to assess aortic regurgitation.…”

Section: Discussionmentioning

confidence: 99%

Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement

et al. 2012

View full text Add to dashboard Cite

“…The rate of thromboembolism in patients undergoing bioprosthetic replacement of the mitral valve, during the first 10 days was 55%/year, 11 to 90 days was 10%/year and after 90 days was 2.4%/year. The complication of MVR was significantly higher than after 10 days [9]. The first several days from surgery are very important for the evaluation of MVR.…”

Section: Discussionmentioning

confidence: 93%

“…Glutaraldehyde and Polyepoxy compounds (Denacol EX-313) have been used for bioprosthetic valves to reduce thrombosis and tissue antigenicity [19,20]. In mitral valve recipients, the rate of thromboembolism during the first 10 days was significantly higher than after 10 days [9]. The first several days from the perioperative period are very important for the evaluation of the MVR.…”

mentioning

confidence: 99%

Short-Term Performance of Mitral Valve Replacement with Porcine Bioprosthetic Valves in Dogs

Takashima¹,

Soda

Tanaka

et al. 2007

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. Porcine bioprosthetic valves cross-linked with glutaraldehyde and polyepoxy compound were newly developed for mitral valve replacement (MVR) in dogs. Five beagle dogs were performed a left thoracotomy and underwent MVR using the porcine bioprosthetic valves during cardiopulmonary bypass (CPB). A vein catheter inserted into right atrium and a vent catheter inserted into the right ventricle to drain. The hemodynamic conditions of CPB were excellent during surgery. The left atrial pressure was measured before and after MVR; there was no significant difference and it was normal. Thrombosis and the prosthetic valve regurgitation were not observed one week after MVR. Pressure half time (PHT) prolonged significantly (P<0.05) from 31.40 ± 4.0 msec presurgery to 99.20 ± 19.4 msec at seven days after MVR, although it indicated the normal range as the bioprosthetic valve. The symptom of the prosthetic valve failure was not observed. This study indicated that the MVR using porcine bioprosthetic valves under CPB might have been effective in dogs as a short-term evaluation. KEY WORDS: bioprosthetic valve, canine cardiopulmonary bypass, mitral regurgitation, mitral valve replacement.

show abstract

High risk of thromboemboli early after bioprosthetic cardiac valve replacement

Cited by 283 publications

References 25 publications

Prosthetic valve thrombosis in a tertiary cardiac centre

Prosthetic valve thrombosis in a tertiary cardiac centre

Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement

Short-Term Performance of Mitral Valve Replacement with Porcine Bioprosthetic Valves in Dogs

Contact Info

Product

Resources

About